moclobemide has been researched along with Bradykinesia in 1 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jouvent, R | 1 |
| Le Houezec, J | 1 |
| Payan, C | 1 |
| Mikkelsen, H | 1 |
| Fermanian, J | 1 |
| Millet, V | 1 |
| Dufour, H | 1 |
1 trial available for moclobemide and Bradykinesia
| Article | Year |
|---|---|
Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
Topics: Adult; Affective Symptoms; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricy | 1998 |